Atherosclerotic cardiovascular disease (ASCVD) is not only a leading cause of mortality among US adults, but also responsible for high medical costs that burden both the healthcare system and individual patients. New research shows that 1 in every 5 patients with ASCVD is unable to afford his or her medical bills, and even among patients with insurance, financial hardship related to medical costs is prevalent.
Atherosclerotic cardiovascular disease (ASCVD) is not only a leading cause of mortality among US adults, but also responsible for high medical costs that burden both the healthcare system and individual patients. New research shows that 1 in every 5 patients with ASCVD is unable to afford his or her medical bills, and even among patients with insurance, financial hardship related to medical costs is prevalent.
The study, slated for publication in the Journal of the American College of Cardiology, drew upon data from 2013 to 2017 from the National Health Interview Survey. Responses from patients who self-reported a diagnosis of coronary or cerebrovascular disease were included in the study, which defined financial hardship as having problems paying medical bills in the past year or needing to pay medical bills off over time. Financial distress was derived from questions related to patients’ level of worry about their ability to pay for such necessities as monthly bills or housing costs.
In total, 6160 of the survey’s respondents aged 18 to 64 reported having ASCVD, and 45.1% (95% CI, 43.4%-47.7%) reported that they had financial hardship related to medical bills. Additionally, 18.9% (95% CI, 17.6%-20.2%) reported that they were unable to pay their medical bills at all. Those who were unable to pay their bills had higher odds of financial distress, food insecurity, and cost-related medication nonadherence compared with patients who did not report financial hardship related to medical bills.
While the highest burden of financial hardship related to medical costs was reported by uninsured and low-income patients, patients who were insured were not immune from the financial toxicity of ASCVD. Among those with insurance, 27% reported financial hardship, and 16.4% reported an inability to pay their bills (versus 20.5% and 38.3%, respectively, among those without insurance.
While the authors note that their study is limited by the fact that it cannot show causality (food insecurity, for example, could contribute to problems paying off medical bills), and the survey questions assessed household financial hardship rather than individual financial hardship, they write that their findings show that the US healthcare system is failing to protect patients with ASCVD from the consequences of financial toxicity.
"It is remarkably disheartening to see how many people suffer severe financial adverse effects of having atherosclerotic cardiovascular disease," said Harlan Krumholz, MD, cardiologist and director of the Yale Center for Outcomes Research and Evaluation (CORE), in a statement on the findings. "We have much work to do to ensure that people are spared the financial toxicity of disease that is imposed by our current healthcare system."
Khurram Nasir, MD, senior author and a faculty member at Yale CORE and in the section of cardiovascular medicine at the Yale School of Medicine, added that this study "sends a strong message to all stakeholders in our cardiology community that financial hardship induced by medical bills isn't just rhetoric for the millions of patients and their families suffering from heart disease and stroke: It's something we can no longer afford to ignore."
Reference
Valero-Elizondo J, Khera R, Saxena A, et al. Financial hardship from medical bills among nonelderly US adults with atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2019;73(6): 727-732. doi: 10.1016/j.jacc.2018.12.004.
Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD
April 8th 2025Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
FDA Approves Vutrisiran to Mitigate Cardiomyopathy-Related Risks and Conditions
March 21st 2025In a recent decision, the FDA approved vutrisiran (amvuttra), making it the only approved therapy for adults with hereditary transthyretin-mediated amyloidosis (ATTR-CM) or wild-type cardiomyopathy.
Read More
Tirzepatide and Semaglutide Improve Weight Loss, Cardiovascular Conditions, but Deemed Too Expensive
March 14th 2025Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they are not cost-effective at their current prices, according to a new evaluation, placing economic burdens on patients with obesity in the US.
Read More